iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments.

Shares of iCAD stock opened at $2.24 on Friday. The firm has a market capitalization of $59.45 million, a PE ratio of -17.23 and a beta of 1.95. The business’s 50-day moving average price is $2. ...

Net Cash Used for Operating Activities: $3.9 million for the full-year 2024. ICAD Inc (NASDAQ:ICAD) reported strong revenue growth, with Q4 2024 revenue reaching $5.4 million, a 14% increase over ...

Greetings. Welcome to the iCAD Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session ...

iCAD, Inc. ( NASDAQ:ICAD ) is possibly approaching a major achievement in its business, so we would like to shine some... iCAD ( NASDAQ:ICAD ) Full Year 2024 Results Key Financial Results Revenue ...

Brown noted that 2024 marked significant AI adoption in healthcare, with iCAD's solutions gaining traction due to their clinical efficiency and diagnostic accuracy improvements. ProFound Detection ...

ICAD ($ICAD) is expected to release its quarterly earnings data on Wednesday, March 19th after market close, per Finnhub. Analysts are expecting revenue of $4,924,050 ...

To accomplish this, NIA selected global technology firm ICAD Holding as its master system integrator (MSI) consultant and partnered with Indian IT major Wipro which will act as a sub-consultant to ...

iCAD partners with RamSoft to integrate AI-powered breast health solutions into radiology platforms, enhancing diagnostic efficiency and patient care. iCAD, Inc. and RamSoft have announced a ...